News Summary: J&J 4Q net income rises 19 percent

STRONG QUARTER: Johnson & Johnson’s fourth-quarter net income jumped 19 percent to $3.52 billion. Revenue rose 4.5 percent to $18.36 billion.

THE DRIVERS: Sales of key prescription drugs and three new ones boosted that business by 12 percent, the consumer health business rebounded as three-quarters of J&J’s recalled nonprescription medicines are now back in stores, and it got a $707 million tax benefit from writing off money-losing subsidiary Scios.

THE FORECAST: J&J expects 2014 earnings per share of $5.75 to $5.85, just below Wall Street’s consensus. Some analysts think it can’t sustain its recent prescription drug sales growth rate. provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language, racial slurs or consistent name calling will be banned. Please be respectful of the opinions of others. If you see an inappropriate comment, please flag it for our moderators to review.

blog comments powered by Disqus